Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections by Díez Martínez, Roberto et al.
1 
 
 Auranofin-loaded nanoparticles as a new therapeutic 
tool to fight streptococcal infections 
 
Roberto Díez-Martínez 1,2,†, Esther García-Fernández 1,2,†, Miguel Manzano 
3,4, Ángel Martínez 3,4, Mirian Domenech 1,2, María Vallet-Regí 3,4 & Pedro 
García 1,2 
 
1 Departamento de Microbiología Molecular y Biología de las Infecciones, Centro de 
Investigaciones Biológicas (CSIC), 28040 Madrid, Spain 
2 CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain 
3 Departamento de Química Inorgánica y Bioinorgánica, Facultad de Farmacia, 
Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de 
Octubre, i+12, Pz/ Ramón y Cajal s/n, 28040, Madrid, Spain 
4 CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain 
† These authors contributed equally 
Correspondence and requests for materials should be addressed to P.G. (email: 
pgarcia@cib.csic.es) or M.V.-R. (email: vallet@ucm.es).  
 
 
 
 
2 
 
Drug-loaded nanoparticles (NPs) can improve infection treatment by ensuring drug 
concentration at the right place within the therapeutic window. Poly(lactic-co-glycolic 
acid) (PLGA) NPs are able to enhance drug localization in target site and to sustainably 
release the entrapped molecule, reducing the secondary effects caused by systemic 
antibiotic administration. We have loaded auranofin, a gold compound traditionally used 
for treatment of rheumatoid arthritis, into PLGA NPs and their efficiency as antibacterial 
agent against two Gram-positive pathogens, Streptococcus pneumoniae and Streptococcus 
pyogenes was evaluated. Auranofin-PLGA NPs showed a strong bactericidal effect as 
cultures of multiresistant pneumococcal strains were practically sterilized after 6 h of 
treatment with such auranofin-NPs at 0.25 µM. Moreover, this potent bactericidal effect 
was also observed in S. pneumoniae and S. pyogenes biofilms, where the same 
concentration of auranofin-NPs was capable of decreasing the bacterial population about 
4 logs more than free auranofin. These results were validated using a zebrafish embryo 
model demonstrating that treatment with auranofin loaded into NPs achieved a noticeable 
survival against pneumococcal infections. All these approaches displayed a clear 
superiority of loaded auranofin PLGA nanocarriers compared to free administration of 
the drug, which supports their potential application for the treatment of streptococcal 
infections.  
 
 
 
 
 
 
 
 
3 
 
Bacterial infections are responsible for significant morbidity and mortality in clinical settings 
and represent a global health threat and a burden to healthcare systems1. Streptococcus 
pneumoniae, the pneumococcus, is a Gram-positive pathogen and a leading cause of diseases 
such as otitis media, bacteremia and meningitis in young children, the elderly, and persons with 
chronic medical conditions. Its clinical burden is about 2 million deaths per year from invasive 
disease (defined as isolation of S. pneumoniae from a normally sterile site such as blood or 
cerebrospinal fluid), half of these in children under 5 years of age, but is likely to cause many 
more due to non-bacteremic pneumonia and other respiratory diseases2. Thus, for every case of 
bacteremic pneumococcal pneumonia in adults, it has been estimated that there are, at least, 3 
additional cases of non-bacteremic pneumococcal pneumonia3. The classical treatment to fight 
pneumococcal infections has been the use of antibiotics, but the effectiveness of this therapy has 
been compromised by the progressive selection for resistance against major drug classes, and 
treatment failures are widely reported4,5. In addition, a smaller, but growing, number of 
pneumococcal isolates are resistant to multiple antibiotics, leaving vancomycin as a drug of last 
choice6. Streptococcus pyogenes is also an important human pathogen being the bacterium most 
frequently isolated from patients with pharyngitis, although it causes more severe invasive 
infections, including necrotizing fasciitis, sepsis, and toxic shock syndrome.  Antibiotic 
treatment failures in cases of streptococcal pharyngitis have been reported, mainly due to the 
biofilm formation7. Consequently, in a recent report, the US Centers for Disease Control and 
Prevention (CDC) has called for an aggressive and immediate action to halt the spread of drug-
resistant pathogens8. 
    It is well established that drug discovery and development is nowadays a very expensive, 
time-consuming, and risky process. The so-called drug ‘repurposing’ (or ‘reprofiling’) is an 
alternative and promising strategy to speed up this drug discovery process, with a concomitant 
reduction of failure rates and associated costs9,10. In this sense, auranofin is a mixed ligand gold 
compound approved by the U.S. Food and Drug Administration (FDA) in 1985, commercialized 
under the brand name of Ridaura, and recommended for the treatment of severe rheumatoid 
arthritis11. Several years ago, new attractive pharmaceutical activities were disclosed for 
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auranofin including anticancer, antiviral and against pathogenic protozoa, like Plasmodium 
falciparum, Entamoeba histolytica, and Giardia lamblia12,13. Although the antibacterial activity 
of auranofin has been less explored, a promising effect on certain Gram-positive pathogens as 
Clostridium difficile14, Staphylococcus aureus15 or Mycobacterium tuberculosis16 has been 
reported in the recent years. 
    One of the most successful strategies for overcoming microbial resistance is the use of 
nanoparticles (NPs) as drug delivery systems, since they can achieve a predictable and desired 
therapeutic effect in the human body17. This effect is reached when the drug plasma 
concentration at the relevant site is within the therapeutic window, that is, below the toxic level 
but above the effective level. Thus, sustained release of antibiotics from NPs could potentially 
improve the treatment efficacy. Additionally, NPs have been used to target antimicrobial agents 
to the site of infection, so that higher doses of drug can be given at the infected site, thereby 
increasing bactericidal activity with fewer adverse side effects18. Poly(lactic-co-glycolic acid) 
(PLGA) is one of the most successfully employed biodegradable polymers because the 
monomers produced after its hydrolysis, lactic acid and glycolic acid, are endogenous and 
efficiently metabolized by the body. In fact, from all the possible biomaterials established for 
the production of NPs, PLGA has engaged the interest of the drug delivery community because 
of its attractive properties. Among them, it is worth to mention: a) the biodegradability and 
biocompatibility; b) its capability for protecting the drug molecules from biodegradation; and c) 
the potential development of sustained release systems19-21. PLGA NPs have been employed for 
vaccine delivery22, cancer treatment23, treatment of inflammatory diseases24,25, on regenerative 
medicine26,27 and even for the treatment of some cardiovascular diseases28. Regarding infection 
treatments, there are some initial studies aimed at developing antibiotic-PLGA NPs to improve 
the treatment of certain bacterial infections. Different antibiotics have been encapsulated into 
PLGA NPs, such as rifampicin and azithromycin29, gentamicin30-32, nafcillin33, and 
sparfloxacin34. After several preclinical evaluations, PLGA NPs have demonstrated their 
antiinfective potential based upon two principles: the NPs are usually taken up by endocytosis, 
so antibiotic-PLGA NPs are promising delivery systems for targeting intracellular infections; 
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and NPs can achieve sustained release, so antibiotic-PLGA NPs can be employed for the 
treatment or prevention of infections. 
    In this work we have explored the use of PLGA NPs loaded with auranofin to demonstrate, as 
a proof of concept, their efficiency as antibacterial agent against two important streptococcal 
pathogens, i.e., S. pneumoniae and S. pyogenes. Promising results have been obtained in in vitro 
assays using multiresistant pneumococcal strains and a biofilm model of S. pneumoniae and S. 
pyogenes, as well as in vivo using a zebrafish embryo infection model. 
 
Results  
Morphology of the NPs. PLGA NPs, both unloaded and auranofin-loaded, were produced 
following the nanoprecipitation method described in Methods section. Auranofin was 
successfully loaded into the PLGA nanocarrier, as digestion experiments confirmed. The 
morphology of NPs was observed by scanning electron microscopy (SEM) (Fig. 1a), showing 
the expected spherical shape of the produced NPs. Loading auranofin during the 
nanoprecipitation stage did not affect the morphology of the particles (data not shown). 
Average diameter and zeta potential. Size of NPs was evaluated using a Dynamic 
Light Scattering (DLS) apparatus. The mean diameter of both unloaded and auranofin-PLGA 
NPs was observed to be ca. 60 nm in both cases (Fig. 1a). The surface characteristics were 
examined through zeta potential, and all NPs were negatively charged with values ca. -30 mV, 
as expected.   
In vitro release kinetics. The employed poly(lactic) acid to poly(glycolic) acid ratio 
together with their molecular weights were selected to follow a certain degradation pattern 
which controls the release kinetics so a constant release of auranofin was achieved in the first 6 
h of the experiment. The release kinetics from PLGA NPs is mainly based on PLGA 
degradation via hydrolysis of its ester linkages in the presence of water. In that case, the typical 
release profile from PLGA NPs should consist on a zero order phase. However, there are other 
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effects influencing the release kinetics, such as surface diffusion, bulk diffusion, polymer 
molecular weight variation and erosion of the NPs. All of them contribute to a complex process 
that is very difficult to reproduce in an individual equation. In our particular case, the auranofin 
release data showed in Fig. 1b can be fitted to a near-zero order kinetic models following the 
equation: 
Qt = Q0 + k tn 
    Being Qt the percentage of auranofin released at time t, Q0 the initial amount of auranofin in 
the solution (normally Q0 = 0), k is the release constant, and n is the factor that is 1 in pure zero-
order release (degradation of polymeric matrix) and 0.5 in Higuchi-type release (diffusion of 
drug molecules). 
    The parameters of the kinetic fitting, shown in Fig. 1b, indicate that our release process is not 
a pure zero release (degradation) neither a pure Higuchi release (diffusion), but somewhere in 
the middle (n= 0.81), a near-zero order kinetic release. 
In vitro bactericidal activity of auranofin-PLGA NPs. To compare the bactericidal 
activity of auranofin alone or auranofin-loaded NPs, we initially chose the noncapsulated strain 
S. pneumoniae R6. It is important to notice that pneumococcal strains show autolysis after 
several hours of stationary phase of growth. Thus, the incubation time was adjusted to take into 
account the release kinetics of auranofin and bacterial autolysis in the conditions tested. The 
compounds were added to a bacterial suspension at an OD550 of 0.6 at three different 
concentrations (0.1, 0.25 and 0.5 µM), and cell optical density was followed throughout the 
growth curve. Viable cell counting demonstrated that auranofin alone was effective as an anti-
pneumococcal agent since 6 h of incubation at 0.5 µM decreased bacterial population for  about 
three log units (Fig. 2a), whereas cultures treated with auranofin-NPs were virtually sterilized at 
concentrations of 0.25 or 0.5 µM (Fig. 2b). Afterwards, the bactericidal activity of auranofin-
loaded NPs was also tested using encapsulated pneumococcal isolates, namely,  strains D39, 48 
and 69 (Table 2). As in the previous assay, free auranofin caused a decrease on viability of 
almost three logs on the multiresistant 48 strain at 0.5 µM (Fig. 2c), whereas auranofin-NPs also 
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led to total killing of the culture even at 0.25 µM (Fig. 2d). Comparable results were obtained 
with the D39 strain (serotype 2) and the multiresistant 69 strain (serotype 19F) (Table 2). To 
confirm that the bactericidal effect was produced by the auranofin released from NPs rather than 
from the NPs themselves, unloaded PLGA NPs were always tested in all the experiments, 
demonstrating that the nanocarrier did not alter the bacterial population. 
    Next, we tested the efficacy of auranofin, alone or loaded in NPs, against two strains of S. 
pyogenes, the type strain and SF370, the latter being a typical biofilm-forming strain. As shown 
in Table 2, the bactericidal effect in these strains did not reach the same levels than those found 
against pneumococcal strains. In fact, free auranofin did not cause any effect on the survival of 
the S. pyogenes type strain, even at the maximum concentration tested (0.5 µM) but provoked a  
90%-drop in the viability of the SF370 strain. It is worth noting, however, that auranofin-NPs 
effectively killed both S. pyogenes strains, with a decrease of 1- and 2-logs on type strain and 
SF370 strain, respectively, confirming the increased efficiency of auranofin when was loaded 
into NPs, compared with auranofin alone.  
    One of the reasons to explain the greater efficacy of auranofin loaded into PLGA NPs against 
the streptococcal pathogens could be due to a better stability of the encapsulated drug and, thus, 
to the protection against a rapid enzymatic and/or hydrolytic degradation26. To investigate this 
issue we performed bactericidal assays against S. pneumoniae R6 adding auranofin pulses each 
hour to simulate the slow release that takes place from the auranofin-NPs.  Adjustment to a final 
concentration of 0.5 µM of auranofin by 6 pulses decreased bacterial population 6 logs after 6 h 
of treatment, while the same concentration of auranofin added at once at the beginning of the 
experiment caused a viability drop of almost 4 logs (Fig. 3). These results strongly suggest that 
treatments with repeated doses of auranofin could be more effective against pneumococcal 
infections than a high single dose. In other words, encapsulation of auranofin in PLGA NPs 
allows a good delivery system since a sustained release of the drug increases the efficiency of 
the treatment. 
Lethal activity of auranofin-PLGA NPs on bacterial biofilm model. Free 
auranofin and auranofin-loaded in NPs were firstly assayed on S. pneumoniae P046 strain at 
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concentrations of 0.25, 0.5 and 1 μM. This biofilm-prone strain does not autolyse after long 
periods of incubation either at 30 °C or 37 °C, due to its deficiency in LytA and LytC 
autolysins. A positive effect of any drug against bacterial biofilm is evidenced by the decrease 
of biofilm formation due to the dispersion of the cells and, most importantly, by the lethal action 
of the drug on the remaining cells. Consequently, the bactericidal effect on the P046 biofilm 
was checked after 6 h of the corresponding treatment and results clearly demonstrated that the 
drug charged in NPs killed more efficiently S. pneumoniae biofilm-grown cells than free 
auranofin. For instance, auranofin-NPs killed about 4 logs of the bacterial population at 0.25 
µM (more than 99.9% mortality), whereas auranofin alone was virtually ineffective at the same 
concentration, being necessary at least 1 µM of compound to achieve 90% mortality (Fig. 4a). 
In addition, we checked the same treatments on S. pyogenes SF370 strain, grown as biofilm, at 
the same concentrations used before. The results in this case were very similar than the 
preceding experiment, as auranofin-NPs at a concentration of 0.25 µM were capable to kill the 
same 4 logs of bacterial cells. It is worth noting a dramatically different behavior in lethal 
activity between free and encapsulated auranofin when compared planktonic and biofilm-grown 
cultures of both pathogens, S. pneumoniae and S. pyogenes. As shown in Fig. 4 and Table 2, 
free auranofin displayed higher bactericidal effect on planktonic than on biofilm cells of S. 
pyogenes SF370 strain (about 1 and 0.5 log decrease, respectively, at 0.5 µM). In contrast, 
auranofin-loaded PLGA NPs were clearly more lethal against biofilm of both bacteria than the 
same cells grown planktonically (>4 and 2 log decrease, respectively, at 0.5 µM for S. 
pyogenes). 
    Once demonstrated the powerful killing effect of auranofin-NPs against two streptococcal 
bacteria grown as biofilm, we analyzed by confocal laser scanning microscopy (CLSM) the fine 
structure of the typical mesh that characterizes this bacterial growth to detect the cell dispersion 
capacity due to the activity of auranofin-NPs. This analysis was made on P046 pneumococcal 
strain and CLSM images of the biofilm in PBS and the corresponding to a control containing 
unloaded PLGA NPs presented similar cell density and percentage of living bacteria (Fig. 5a, 
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b). In contrast, the biofilm treated with auranofin-NPs evidenced the great loss of remaining 
pneumococcal cells (Fig. 5c), which fully confirmed the lethal action of auranofin when is 
loaded in PLGA NPs. 
Antibacterial activity in an animal model. To validate in an animal model of 
infection the in vitro bactericidal results of auranofin-NPs, we employed a zebrafish embryo 
model, which has been recently set up for S. pneumoniae and S. pyogenes35. Control 
experiments using the pneumococcal strain D39 showed that a bacterial challenge with about 
2.5 × 108 CFU mL−1 killed 50% of the embryos in 4−5 days, when administered by immersion 
in E3 medium. Therefore, at 48 h post fecundation, zebrafish embryos were brought in contact 
with the pathogen. Eight hours after bacterial challenge, embryos were extensively washed with 
the same medium and treated with a single dose of free auranofin or auranofin-NPs at 
concentrations ranging from 0.1 to 0.5 µM per embryo. Heat-killed (10 min at 65 °C) D39 strain 
cells were used as negative control. Rescue of the embryos infected and treated with auranofin-
NPs varied depending on the concentration used, i.e., 100% survival (46/46) when treated with 
0.5 µM, 93.5% (43/46) with 0.25 µM, and 89.1% (41/46) with 0.1 µM. These results indicated 
the efficiency of auranofin to protect embryos from pneumococcal infection and also that 
treatment with the auranofin-NPs resulted in about 15% greater protection (P < 0.01) than with 
the drug alone, e.g. 73.9% of embryos (34/46) survived when treated with free auranofin and 
89.1% with auranofin-NPs, both at the same concentration (0.1 µM) (Fig. 6). The effectiveness 
of auranofin on embryo rescue was compared with that of a conventional antibiotic like 
ampicillin, which belongs to the β-lactam family. When both drugs were added alone at 0.5 µM 
the zebrafish embryo survival was almost the same after 5 days post infection (84.6%) (Fig. 6a). 
However, treatments with the same concentration of ampicillin loaded into PLGA NPs rescued 
a similar rate of embryos (38/46 that means 82.6%), whereas auranofin-NPs achieved 100% of 
survival at the same concentration of 0.5 µM (Fig. 6b). To visualize the protection effect of 
auranofin-NPs, embryos from all groups of experiments were monitored over time for any 
morphological change. Embryos were examined using a stereomicroscope and it was found that 
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embryos infected with S. pneumoniae D39 had a much shorter and curved tail and several 
deformities, mainly in pericardial cavity and yolk sac (Fig. 7b) compared to the corresponding 
uninfected controls (Fig. 7a). However, infected embryos and treated with 0.5 µM of auranofin-
NPs were fully protected and did not show the typical deformities provoked by pneumococcal 
infection (Fig. 7c).  
 
Discussion 
Infections caused by multiresistant bacteria are of important concern in terms of global health as 
they often promote lethal pathologies. It is becoming clear the particular relevance of biofilm-
derived infections since after treatment with high concentrations of antibiotics most of the 
bacteria survived in such biofilms, even when dead bacterial cells covered the surface7. Disease 
treatments have been hampered mainly due to the lack of effective antibiotics; hence, the 
identification of new drugs with novel mechanisms of action has become an international 
priority36,37. Auranofin is a drug with a gold(I) center coordinated to a thiosugar and 
triethylphosphine residues, which has been recently repurposed as an efficient drug not only 
against pathogenic protozoa12,13 but also against several Gram-positive and Gram-negative 
bacteria, although the latter group was less susceptible to the drug than the former. In fact, MIC 
values for the most susceptible tested Gram-positive bacteria ranged between 0.12 and 0.5 µg 
mL−1, whereas these MICs increased to >16 µg mL−1 for some Gram-negative bacteria, like 
Klebsiella pneumoniae, Pseudomonas aeruginosa or Acinetobacter baumannii15,16. Although the 
detailed mechanism of the bactericidal effect of auranofin has not been elucidated, recent data 
strongly suggested that the thiol-redox homeostasis is the bacterial target in M. tuberculosis16. It 
was demonstrated that auranofin inhibits the bacterial thioredoxin reductase, a key protein in 
many Gram-positive bacteria for maintaining the thiol-redox balance and protecting against 
reactive oxidative species15. 
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Initially, we focused this study on the bactericidal effect of auranofin against two clinically 
relevant pathogens, S. pneumoniae and S. pyogenes. A summary of viability data, shown in 
Table 2, demonstrated that this drug has a potent bactericidal effect against all the 
pneumococcal strains tested, including the multiresistant ones, whereas it was rather inefficient 
against the S. pyogenes strains assayed. The value of the lethal concentration for pneumococci, 
0.5 µM corresponds to 0.34 µg mL-1, is in the range of the MIC values reported for other Gram-
positive bacteria as S. aureus and Streptococcus epidermidis16,38. After these promising results 
with the reprofiled auranofin against pneumococci, we looked for a method to improve and 
extend the bacteriolytic action of the drug, even in biofilm assays where bacterial population is 
more tolerant, or resistant, to antibiotic therapies. A typical solution to achieve this goal in the 
formulation of active compounds is loading of the desired drug in an appropriate vehicle or NP.  
Polymers have been employed by the pharmaceutical industry for more than 40 years, 
evolving from resorbable sutures and orthopaedic implants to multifunctional NPs able of 
targeting and controlled release of therapeutics. In this sense, the use of polymeric NPs for 
developing safer and more effective medicines, so-called nanomedicines, has substantially 
influenced the pharmaceutical and biotechnological industries. Among others, biodegradable 
PLGA NPs have been widely  employed for a variety of biological applications thanks to their 
reliable methods of preparation, the biocompatibility (FDA-approved), biodegradability39,40, the 
capacity to encapsulate and protect drugs from degradation21,41. Additionally, active molecule 
entrapping (or encapsulating) within a delivery system provides a greater control of the 
pharmacokinetic behavior of the desired drug. This more efficient use of pharmaceutical 
compounds may diminish some of the drawbacks and supplies the basis for shortening the 
current time required by classical treatments. This might be of capital importance when dealing 
with antibiotics, because it could help to avoid the resistance of bacteria to antibiotics, which is 
one of the main concerns in the treatment of infections nowadays. There are many examples in 
the literature where the encapsulation of antibiotics into PLGA NPs increases their efficiency. 
For example, azithromycin loaded PLGA NPs were more active than azithromycin solution 
against Salmonella typhi42. More recently it has been described that clarithromicine-PLGA NPs 
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are more effective than untreated clarithromicine against E. coli, H. influenzae, S. aureus and S. 
pneumoniae43. Given the advantages showed by PLGA NPs and taking into account the 
improved efficacy of antibiotics when loaded in this delivery system, we prepared auranofin-
PLGA NPs with a protocol that allowed the reproducible formation of NPs exhibiting diameters 
below 100 nm and low polydispersity indexes, which is indicative of a homogeneous size 
distribution.  
Once the loading and sustained release of auranofin from PLGA NPs was confirmed, their 
potential benefits for infection treatments were evaluated. Specifically, preparation of auranofin-
PLGA allowed the comparison of its lethal activity against S. pneumoniae and S. pyogenes with 
that of auranofin alone using three kinds of experiments as model systems: i) in vitro study 
using several pneumococcal strains, including relevant multiresistant ones; ii) biofilm assay on 
appropriate strains, like S. pneumoniae P046 and S. pyogenes SF370; iii) in vivo animal model, 
like zebrafish embryos infected with S. pneumoniae. All these approaches confirmed the 
improved killing activity of auranofin-NPs over the free auranofin with particular emphasis on 
the biofilm approach, since the potency of auranofin loaded into PLGA to disperse and kill 
bacterial population of S. pneumoniae and S. pyogenes biofilms exceeded about 4 logs the 
lethality found with the drug alone against both pathogens. This promising result could be 
especially relevant in foreseeing a future treatment of biofilm-based infections that are 
particularly recalcitrant to classical antibiotics44. An additional argument to count on clinical 
application of this kind of NPs comes from the successful validation of in vitro assays with the 
protection to infected zebrafish embryos, which highlights the benefits of NPs as drug delivery 
system to combat streptococcal infections.  
 
Methods  
NP preparation. The nanoprecipitation method for the formation of auranofin-encapsulated 
PLGA NPs was carried out according to a previously described procedure45. Briefly, 10−15 mg 
of auranofin [Sigma-Aldrich, >98% High Performance Liquid Chromatography (HPLC)] were 
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dissolved in 20 mL of a mixture of dichloromethane:acetone (0.5:19.5), and then 200 mg of 
PLGA (Aldrich, 50:50, Mw 7,000-17,000) were added and subsequently sonicated for 2 min 
(solution 1). Separately, 56 mg of Pluronic F-68 (Sigma) were dissolved in 40 mL of water 
(0.14% w v−1) in a 100 mL round bottom flask under moderate magnetic stirring (solution 2). 
Solution 1 was placed on a syringe dispenser to be then transferred dropwise (0.25 mL min−1) 
over solution 2 under moderate magnetic stirring. The NPs were stirred for 2 h, and the 
remaining organic solvent was removed in a rotary evaporator at reduced pressure for 2 h. The 
NPs were then centrifuged at 6,600 rpm in a 7700 RCF rotor at 4 °C for 15 min, washed twice 
with distilled water and centrifuged again. Then, the NPs were suspended in a small amount of 
water, flash frozen in liquid nitrogen and freeze-dried. The same process was followed without 
auranofin for the synthesis of unloaded PLGA NPs.   
Morphology of the produced NPs. The spherical morphology of the produced NPs was 
evaluated using SEM on a JEOL JSM 6335F (Electron Microscopy Centre, UCM). The samples 
underwent Au metallization prior to observation. 
Determination of particle sizes and polydispersities. The average hydrodynamic 
size and the polydispersity index were measured with a DLS apparatus (Zetasizer NanoZS, 
Malvern Instruments) equipped with a 633 nm laser at 25 ºC. Samples from the prepared 
suspensions with ultra-purified water (about 0.1 mg mL-1) were placed in the measurement cell.  
Drug loading and encapsulation efficiency.  Auranofin was quantified measuring 
Au in an acid-digested sample by Inductively Coupled Plasma Atomic Emission 
Spectroscopy (ICP-AES, Varian Vista AX Pro) through the Au emission line at 267.6 nm. 
Briefly, 10 mg of auranofin-loaded NPs were precisely weighed and placed in a reactor Teflon-
jacketed steel case. Then, 10-20 mL of concentrated hydrofluoric/nitric acid (1:1) (Panreac) 
were gently added and moderately heated until complete digestion for 48 h. Finally, the clear 
yellow solution was taken to 10 mL volumetric flask and measured. The achieved drug loading 
was 1.8-6.2 mg of auranofin per gram of NPs in all synthesis. 
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In vitro release of auranofin from PLGA NPs. In vitro release studies were carried 
out dispersing 10 mg of loaded PLGA NPs in 0.5 mL of fresh phosphate-buffered saline (PBS) 
solution (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4 [adjusted to pH 
7.4]) and placed on a Transwell permeable support with a 0.4 µm (average pore size) 
polycarbonate membrane. The well was filled with 1.0 mL of PBS pH 7.4 and the suspension 
was orbitally shaken at 100 rpm at 37 ºC during all the experiment.  Every hour, 1 mL of sample 
was removed from the Transwell plate and replaced with fresh PBS. The separation and 
quantification was carried out by HPLC equipped with UV-Vis detector, measuring the 
absorbance of 2-nitro-5-thiobenzoate (NTB, λmax 409 nm). NTB is produced when thiol groups 
react with 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) cleaving the disulphide bond to obtain 
NTB in water at neutral pH. The samples containing auranofin were treated with KI to break the 
gold-thiol bond46. With this purpose 250 μL of sample with 50 μL KI 2.0 M were placed in an 
ultrasound bath at 50 ºC for 20 min, then immediately ice-cooled, according to the standard 
protocol provided by Sigma. An HPLC (Waters Alliance 2695) separation module (Milford, 
Massachusetts, USA) based on a isocratic mobile phase of ACN:MeOH:Water (3:3:94, v:v:v) at 
a flow rate of 1 mL min-1 was used to separate and quantify the NTB signal with a 4.2 min of 
retention time. The system was equipped with a variable wavelength diode array detector Water 
2996 at 354 nm. A Waters X-Terra RP-18 reverse phase column (4.6 x 250 mm, 5 µm) was 
employed at 40 ºC and 10-50 μL injection volume was selected upon the case. A scheme 
describing the reactions, the protocol for derivatization of auranofin, and the 3D 
chromatogram is shown in Fig. S1. 
Bactericidal assays. Bactericidal effects of the auranofin-loaded NPs were monitored by 
following the optical density at 550 nm (OD550) for 6 h and the viable cells at this time point. 
Briefly, S. pneumoniae and S. pyogenes strains  (Table 1) were grown in C medium47 and Todd-
Hewitt medium, respectively, supplemented with yeast extract (0.8 mg mL−1; Difco 
Laboratories) at 37 °C without shaking. Once the bacteria reached the exponential phase of 
growth (OD550 ≈0.3), the cultures were centrifuged and washed twice with PBS, and the final 
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OD550 was adjusted to ≈0.6 with PBS. Resuspended bacteria were then transferred into plastic 
tubes, and different amounts of auranofin-PLGA NPs (suspended in PBS) were added to reach a 
final concentration of 0.1, 0.25, or 0.5 µM auranofin. Control samples with unloaded PLGA 
NPs or auranofin alone at the same concentrations were always run in parallel. Additional 
controls with PBS and dimethylsulfoxide (DMSO), used to solubilize NPs and auranofin, 
respectively, were also included. All samples were incubated at 37 °C for 6 h, and the OD550 and 
viable cells were determined at selected time points. Viable cell counting was carried out in 
tryptose blood agar base plates (Difco Laboratories) supplemented with 5% defibrinated sheep 
blood. For each sample, a 10-fold dilution series was prepared in PBS, and 10 μL of each 
dilution were plated. Colonies were counted after overnight incubation at 37 °C.  
Biofilm assay. Pneumococcal biofilms were produced using S. pneumoniae strain P046, a 
double lytA lytC mutant48, a derivative from the unencapsulated laboratory strain R649. The 
optimal conditions for biofilm formation on polystyrene plates have been described elsewhere50. 
In short, all biofilms were formed in Costar 3595 96-well polystyrene microtiter plates 
(Corning, New York, USA). Cells were grown in C medium supplemented with yeast extract 
(0.8 mg mL−1) to an optical density of 0.5–0.6 at OD595, sedimented by centrifugation, 
resuspended in an equal volume of C medium, diluted, and portions of  200 μL containing 2.2 
 104 CFU were dispensed into each well. After 16 h of incubation at 34 °C, the planktonic 
cultures were removed and the resulting biofilms were washed twice with PBS and then treated 
for additional 6 h at 37 °C with various concentrations of auranofin or auranofin-NPs. Controls 
with DMSO or unloaded NPs were also assayed. Afterwards, the supernatants were removed 
again, washed twice with PBS and 10-fold dilution series were prepared in PBS. 10 μL of each 
dilution were plated in blood agar plates and colonies were counted after overnight incubation at 
37 °C. The S. pyogenes biofilm was produced using SF370 strain, as previously described51. 
Briefly, an overnight culture of S. pyogenes was diluted 1:20 with fresh Todd-Hewitt medium 
supplemented with yeast extract (0.8 mg mL−1) and grown statically in polystyrene microtiter 
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plates for 24 h at 37 °C. After incubation, the same protocol was followed as described above 
for the pneumococcal biofilms.  
Microscopy observation of biofilms. To observe biofilms by CLSM, S. pneumoniae 
P046 strain was grown on glass-bottomed WillCo-dishes (WillCo Wells) for 16 h at 34 °C. 
Following incubation, the culture medium was removed and the biofilm rinsed with PBS to 
remove non-adherent bacteria and then treated for additional 6 h at 37 °C with 1 μM of 
auranofin-NPs. Control biofilms with PBS or unloaded PLGA NPs were also assayed. 
Afterwards, the supernatants were removed again and then stained with the LIVE/DEAD 
BacLight bacterial viability kit L-13152 (Invitrogen-Molecular Probes) for monitoring the 
viability of bacterial populations. Cells with a compromised membrane ― considered dead or 
dying― stain red, whereas those with an intact membrane stain green48. The biofilms were 
observed at 63 magnification using a Leica TCS-SP2-AOBS-UV CLSM. The 
excitation/emission maxima were around 488/500–546 nm. Images were analyzed using LCS 
software (Leica). Projections were obtained through the x–y plane (individual scans at 0.5-μm 
intervals).  
Zebrafish embryo infection assay.  The pneumococcal infection model was based 
on a method described previously35, using wild-type zebrafish embryos (Danio rerio) 
obtained from ZFBioLabs (Tres Cantos, Spain). Briefly, embryos were dechorionated at 
24 h post fecundation by treatment with pronase (2 mg mL−1) for 1 min, distributed in 
96-well plates and incubated in 100 µL of E3 medium. At 48 h post fecundation, 
embryos were infected with 100 µL of a 2.5 × 108 colony-forming units (CFU) mL−1 
suspension of S. pneumoniae strain D39. Bacterial inoculation titers were calculated by 
serial dilution and plating onto tryptose blood agar plates for each experiment. Seven 
hours post infection, infected embryos were extensively washed with E3 medium to 
remove the bacteria and 100 µL of the same autoclaved fresh medium supplemented 
with auranofin (0.1, 0.25 or 0.5 µM) or auranofin-loaded NPs (containing the same 
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concentration of the drug) were added. Non-infected controls without treatment or 
treated either with DMSO, auranofin, or unloaded PLGA NPs were washed in the same 
way. Embryos were incubated at 27.5 °C under sterile conditions and mortality was 
followed in all samples for 5 days, changing fresh E3 medium every day. Zebrafish 
embryos were considered dead when coagulation was observed as well as absence of 
heartbeat during 15 seconds observation. Each experiment was repeated at least 3 times, 
and 24 to 36 embryos were used per condition and experiment. 
Imaging analysis. Live embryos (5 days post infection) were anesthetized by 
immersion in tricaine (MS-222) (Sigma-Aldrich) at 200 mg mL−1, mounted in 3% 
methylcellulose in depression slides and photographed under an Olympus SZX16 
stereoscope with a QImaging MicroPublisher 5.0 RVT camera. Images were processed 
with NIH ImageJ. For all the experiments described, the images shown are 
representative of the effects observed in at least 90% of the individuals. 
Statistical analysis. All in vitro results are representative of data obtained from 
repeated independent experiments, and each value represents the mean standard 
deviations for 3 to 4 replicates. Statistical analysis was performed by using the two-
tailed Student’s t test (for two groups), whereas analysis of variance (ANOVA) was 
chosen for multiple comparisons. For all in vivo data, the log-rank (Mantel-Cox) and 
Gehan-Breslow-Wilcoxon tests were used to draw, analyze and compare the survival 
curves. GraphPad InStat version 5.0 (GraphPad Software, San Diego, CA) was used for 
statistical analysis. 
 
References 
 
18 
 
1 WHO. Antimicrobial resistance, global report on surveillance, 
<http://www.who.int/drugresistance/documents/surveillancereport/en/.> (2014). 
2 O'Brien, K. L. et al. Burden of disease caused by Streptococcus pneumoniae in 
children younger than 5 years: global estimates. Lancet 374, 893−902 (2009). 
3 Said, M. A. et al. Estimating the burden of pneumococcal pneumonia among adults: 
a systematic review and meta-analysis of diagnostic techniques. PloS one 8, e60273 
(2013). 
4 Klugman, K. P. Bacteriological evidence of antibiotic failure in pneumococcal lower 
respiratory tract infections. Eur. Respir. J. 20 (Suppl. 36), 3s-8s (2002). 
5 Fuller, J. D. & Low, D. E. A review of Streptococcus pneumoniae infection treatment 
failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41, 118−121 
(2005). 
6 Jernigan, D. B., Cetron, M. S. & Breiman, R. F. Minimizing the impact of drug-
resistant streptococcus pneumoniae (DRSP): A strategy from the DRSP working 
group. JAMA : the journal of the American Medical Association 275, 206-209 (1996). 
7 Ogawa, T. et al. Biofilm formation or internalization into epithelial cells enable 
Streptococcus pyogenes to evade antibiotic eradication in patients with pharyngitis. 
Microb. Pathog. 51, 58-68 (2011). 
8 McCarthy, M. CDC calls for urgent action to combat rise of drug resistant pathogens. 
British Med. J. 347, f5649 (2013). 
9 Chong, C. R. & Sullivan, D. J., Jr. New uses for old drugs. Nature 448, 645−646 (2007). 
10 Aronson, J. K. Old drugs – new uses. Br. J. Clin. Pharmacol. 64, 563-565 (2007). 
11 Shaw, C. F. Gold-based therapeutic agents. Chem. Rev. 99, 2589-2600 (1999). 
12 Madeira, J. M., Gibson, D. L., Kean, W. F. & Klegeris, A. The biological activity of 
auranofin: implications for novel treatment of diseases. Inflammopharmacol. 20, 
297−306 (2012). 
13 Roder, C. & Thomson, M. Auranofin: Repurposing an old drug for a golden new age. 
Drugs in R&D 15, 13-20 (2015). 
14 Jackson-Rosario, S. et al. Auranofin disrupts selenium metabolism in Clostridium 
difficile by forming a stable Au−Se adduct. J. Biol. Inorg. Chem. 14, 507−519 (2009). 
15 Hokai, Y. et al. Auranofin and related heterometallic gold(I)−thiolates as potent 
inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains. J. Inorg. 
Biochem. 138, 81−88 (2014). 
16 Harbut, M. B. et al. Auranofin exerts broad-spectrum bactericidal activities by 
targeting thiol-redox homeostasis. Proc. Natl. Acad. Sci. USA 112, 4453-4458 (2015). 
17 Kandi, V. & Kandi, S. Antimicrobial properties of nanomolecules: potential 
candidates as antibiotics in the era of multi-drug resistance. Epidemiol. Health 37, 
e2015020 (2015). 
18 Leid, J. G. et al. In vitro antimicrobial studies of silver carbene complexes: activity of 
free and nanoparticle carbene formulations against clinical isolates of pathogenic 
bacteria. J. Antimicrob. Chemother. 67, 138-148 (2012). 
19 Vert, M., Mauduit, J. & Li, S. Biodegradation of PLA/GA polymers: increasing 
complexity. Biomaterials 15, 1209-1213 (1994). 
20 Prokop, A. & Davidson, J. M. Nanovehicular intracellular delivery systems. J. Pharm. 
Sci. 97, 3518-3590 (2008). 
21 Danhier, F. et al. PLGA-based nanoparticles: an overview of biomedical applications. 
J. Control Release 161, 505-522 (2012). 
22 Mahapatro, A. & Singh, D. Biodegradable nanoparticles are excellent vehicle for site 
directed in-vivo delivery of drugs and vaccines. J. Nanobiotechnol. 9, 55 (2011). 
23 Cheng, J. et al. Formulation of functionalized PLGA–PEG nanoparticles for in vivo 
targeted drug delivery. Biomaterials 28, 869-876 (2007). 
19 
 
24 Meissner, Y., Pellequer, Y. & Lamprecht, A. Nanoparticles in inflammatory bowel 
disease: particle targeting versus pH-sensitive delivery. Int. J. Pharm. 316, 138-143 
(2006). 
25 Meissner, Y. & Lamprecht, A. Alternative drug delivery approaches for the therapy of 
inflammatory bowel disease. J. Pharm. Sci. 97, 2878-2891 (2008). 
26 Panyam, J. & Labhasetwar, V. Biodegradable nanoparticles for drug and gene 
delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 329-347 (2003). 
27 Ladewig, K. Drug delivery in soft tissue engineering. Expert Opin. Drug Deliv. 8, 1175-
1188 (2011). 
28 Lim, H. J. et al. A novel technique for loading of paclitaxel-PLGA nanoparticles onto 
ePTFE vascular grafts. Biotechnol. Prog. 23, 693-697 (2007). 
29 Toti, U. S. et al. Targeted delivery of antibiotics to intracellular chlamydial infections 
using PLGA nanoparticles. Biomaterials 32, 6606-6613 (2011). 
30 Lecaroz, C., Gamazo, C. & Blanco-Prieto, M. J. Nanocarriers with gentamicin to treat 
intracellular pathogens. J. Nanosci. Nanotechnol. 6, 3296-3302 (2006). 
31 Lecaroz, M. C., Blanco-Prieto, M. J., Campanero, M. A., Salman, H. & Gamazo, C. 
Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and 
pharmacodynamics in Brucella melitensis- infected mice. Antimicrob. Agents 
Chemother. 51, 1185-1190 (2007). 
32 Imbuluzqueta, E. et al. Novel bioactive hydrophobic gentamicin carriers for the 
treatment of intracellular bacterial infections. Acta Biomater. 7, 1599-1608 (2011). 
33 Pillai, R. R., Somayaji, S. N., Rabinovich, M., Hudson, M. C. & Gonsalves, K. E. 
Nafcillin-loaded PLGA nanoparticles for treatment of osteomyelitis. Biomed. Mater. 
3, 034114 (2008). 
34 Gupta, H. et al. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug 
delivery. Nanomedicine : nanotechnology, biology, and medicine 6, 324-333 (2010). 
35 Díez-Martínez, R. et al. Improving the lethal effect of Cpl-7, a pneumococcal phage 
lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-
binding module. Antimicrob. Agents Chemother. 57, 5355–5365 (2013). 
36 Spellberg, B., Bartlett, J., Wunderink, R. & Gilbert, D. N. Novel approaches are 
needed to develop tomorrow’s antibacterial therapies. Am. J. Respir. Crit. Care Med. 
191, 135-140 (2015). 
37 Gadakh, B. & Aerschot, A. V. Renaissance in antibiotic discovery: some novel 
approaches for finding drugs to treat bad bugs. Curr. Med. Chem., (in press) (2015). 
38 Cassetta, M., Marzo, T., Fallani, S., Novelli, A. & Messori, L. Drug repositioning: 
auranofin as a prospective antimicrobial agent for the treatment of severe 
staphylococcal infections. Biometals : an international journal on the role of metal 
ions in biology, biochemistry, and medicine 27, 787-791 (2014). 
39 Avgoustakis, K. et al. PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle 
degradation, in vitro drug release and in vivo drug residence in blood properties. J. 
Control Release. 79, 123-135 (2002). 
40 Makadia, H. K. & Siegel, S. J. Poly lactic-co-glycolic acid (PLGA) as biodegradable 
controlled drug delivery carrier. Polymers (Basel) 3, 1377-1397 (2011). 
41 Anderson, J. M. & Shive, M. S. Biodegradation and biocompatibility of PLA and PLGA 
microspheres. Adv. Drug Deliv. Rev. 28, 5-24 (1997). 
42 Mohammadi, G. et al. Development of azithromycin–PLGA nanoparticles: 
physicochemical characterization and antibacterial effect against Salmonella typhi. 
Colloids Surf. B Biointerfaces. 80, 34-39 (2010). 
43 Valizadeh, H. et al. Antibacterial activity of clarithromycin loaded PLGA 
nanoparticles. Die Pharmazie 67, 63-68 (2012). 
20 
 
44 Lebeaux, D., Ghigo, J.-M. & Beloin, C. Biofilm-related infections: bridging the gap 
between clinical management and fundamental aspects of recalcitrance toward 
antibiotics. Microbiol. Mol. Biol. Rev. 78, 510-543 (2014). 
45 Fonseca, C., Simões, S. & Gaspar, R. Paclitaxel-loaded PLGA nanoparticles: 
preparation, physicochemical characterization and in vitro anti-tumoral activity. J. 
Control Release 83, 273-286 (2002). 
46 Kizu, R., Kaneda, M., Yamauchi, Y. & Miyazaki, M. Determination of auranofin, a 
chrysotherapy agent, in urine by HPLC with a postcolumn reaction and visible 
detection. Chem. Pharm. Bull (Tokyo) 41, 1261-1265 (1993). 
47 Lacks, S. & Hotchkiss, R. D. A study of the genetic material determining an enzyme 
activity in Pneumococcus. Biochim. Biophys. Acta 39, 508−518 (1960). 
48 Moscoso, M., García, E. & López, R. Biofilm formation by Streptococcus pneumoniae: 
role of choline, extracellular DNA, and capsular polysaccharide in microbial 
accretion. J. Bacteriol. 188, 7785−7795 (2006). 
 49 Hoskins, J. et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J. 
Bacteriol. 183, 5709−5717 (2001). 
50          Domenech, M., García, E. & Moscoso, M. In vitro destruction of Streptococcus 
pneumoniae biofilms with bacterial and phage peptidoglycan hydrolases. 
Antimicrob. Agents Chemother. 55, 4144–4148 (2011).  
51          Shen, Y., Köller, T., Kreikemeyer, B. & Nelson, D. C. Rapid degradation of 
Streptococcus pyogenes biofilms by PlyC, a bacteriophage-encoded endolysin. J. 
Antimicrob. Chemother. 68, 1818-1824 (2013). 
52 Lanie, J. A. et al. Genome sequence of Avery's virulent serotype 2 strain D39 of 
Streptococcus pneumoniae and comparison with that of unencapsulated laboratory 
strain R6. J. Bacteriol. 189, 38−51 (2007). 
53 Soriano, F. et al. Breakthrough in penicillin resistance? Streptococcus pneumoniae 
isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and 
geographical relatedness. J. Antimicrob. Chemother. 62, 1234−1240 (2008). 
 
Acknowledgements 
We thank E. García for critical reading of the manuscript. The excellent technical assistance of 
E. Cano is greatly appreciated. This research was funded by grants from Ministerio de 
Economía y Competitividad, Spain (SAF2012-39444-C02-01, MAT2012-35556 and CSO2010-
11384-E, Ageing Network of Excellence). We also thank the National Electron Microscopy 
Center at UCM for the SEM analyses. 
 
21 
 
Additional Information 
Affiliations 
Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, 
Ramiro de Maeztu 9, 28040, Madrid, Spain. 
Roberto Díez-Martínez, Esther García-Fernández, Mirian Domenech and Pedro García. 
CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III 
(ISCIII). Madrid, Spain. 
Roberto Díez-Martínez, Esther García-Fernández, Mirian Domenech and Pedro García. 
Departamento de Química Inorgánica y Bioinorgánica, Facultad de Farmacia, 
Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de 
Octubre, i+12, Pz/ Ramón y Cajal s/n, 28040, Madrid, Spain 
Miguel Manzano, Ángel Martínez and María Vallet-Regí 
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain 
Miguel Manzano, Ángel Martínez and María Vallet-Regí 
 
Author Contributions  
M.V-R. and P.G. conceived the research. R.D-M, E.G-F., M.M., M.V-R. and P.G. designed the 
experiments. R.D-M., E.G-F., M.D., A.M. and M.M. performed the experiments and analyzed 
the data. 
R.D-M., E.G-F., M.M., M.V-R. and P.G. wrote the paper. All authors discussed the results, 
edited, and approved the manuscript. 
 
Competing financial interests 
The authors declare no competing financial interests. 
 
22 
 
 
 
 
 
Table 1. Bacterial strains used in this study. 
Strain Relevant description Source or reference
S. pneumoniae   
  R6 D39 derivative; non-encapsulated 49 
  D39 Serotype 2 52 
  48 Serotype 23F; penicillin MICa = 16 mg L−1; 
erythromycin MICa >128 mg L−1; ciprofloxacin MICa = 
1 mg L−1; levofloxacin MICa = 1 mg L−1; 
chloramphenicol MICa = 4 mg L−1 ; tetracycline MICa  
>64 mg L−1  
53 
 69 Serotype 19F; penicillin MICa = 2 mg L−1; 
erythromycin MICa  = 16 mg L−1 ; levofloxacin MICa  = 
1 mg L−1; chloramphenicol MICa  = 4 mg L−1; 
tetracycline MICa  = 64 mg L−1 
53 
P046 lytAlytC mutant  48 
S. pyogenes   
 Type strain  CECTb 985 
 SF370 Serotype M1; biofilm-forming strain CECTb 5109 
a MIC, Minimum Inhibitory Concentration. 
b CECT, Colección Española de Cultivos Tipo. 
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Table 2. Bacterial viability after treatment with auranofin or auranofin-PLGA NPsa. 
Organism (serotype) 
Viability after 6 h of treatment withb: 
Auranofin (µM) PLGA-auranofin (µM) 
DMSO 0.1 0.25 0.5 PLGA 0.1 0.25 0.5 
S. pneumoniae         
  R6 (none) − + + +++ − ++++ * * 
  D39 (2) − ++ ++ +++ − ++++ ++++ * 
  48 (23F) − + + +++ − ++++ * * 
  69 (19F) − ++ ++ +++ − ++++ ++++ * 
S. pyogenes         
  Type strain − − − − − − − + 
  SF370 (M1) − − − + − + ++ ++ 
a Bacteria were incubated at 37 °C in PBS (OD550 ≈ 0.6) with the indicated compound at 0.1, 
0.25 or 0.5 µM. Viability was determined after 6 h of incubation. 
b  −, no effect; +, decrease of 1 log in viable cells;++, decrease of 2 logs in viable cells; +++, 
decrease of 3 logs in viable cells; ++++, decrease of  ≥ 4 logs in viable cells; *, < 10 CFU 
mL−1. 
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Figure Legends  
Figure 1. Auranofin and PLGA NPs. (a) SEM micrograph of unloaded PLGA NPs and size 
distribution of PLGA NPs measured by DLS (inset). (b) In vitro release of auranofin from 
PLGA NPs and kinetic fitting (dashed line) of the release kinetics according to a near-zero 
order. Chemical structure of auranofin is inserted in the panel. Ac, acetyl; Et, ethyl. 
Figure 2. Bactericidal effects of auranofin and auranofin-PLGA NPs against 
pneumococcal strains. Exponentially growing cultures of R6 strain (a and b) and 48 strain (c 
and d) were incubated in the absence or in the presence of auranofin alone (a and c) or 
auranofin-NPs (b and d).  Controls with PBS buffer, DMSO or PLGA without auranofin were 
included. Viable cells were determined on blood agar plates after 6 h of incubation at 37 °C. 
Data are means of four independent experiments. Error bars represent standard deviations, and 
asterisks indicate that results are statistically significant compared to the control in the absence 
of auranofin (one-way ANOVA with a post hoc Dunnet test; *, P <0.01; **, P <0.001). 
Figure 3. Bactericidal effects of auranofin pulses against S. pneumoniae R6. Exponentially 
growing cultures were incubated in the presence of a final concentration of 0.5 µM of auranofin 
added in three different conditions: as a single dose at the beginning of the experiment 
(auranofin), by 1 h pulses for 6 h (auranofin-pulses), or loaded into PLGA NPs (auranofin-
PLGA NPs). Controls with PBS buffer, DMSO or PLGA without auranofin were also included. 
Viable cells were determined on blood agar plates after 6 h of incubation at 37 °C. Data are 
means of three independent experiments. Error bars represent standard deviations, and asterisks 
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indicate that results are statistically significant compared to the control in the absence of 
auranofin (one-way ANOVA with a post hoc Dunnet test; *, P <0.01; **, P <0.001). 
Figure 4. Streptococcal biofilms treated with auranofin or auranofin-PLGA NPs. (a) Cells 
of S. pneumoniae P046 strain, grown as biofilm, were treated with 0.25, 0.5 and 1 µM of 
auranofin and auranofin-PLGA NPs for 6 h at 37 °C. (b) Cells of S. pyogenes SF370 strain, 
grown as biofilm, were treated with 0.25, 0.5 and 1 µM of auranofin and auranofin-PLGA NPs 
for 6 h at 37 °C. Controls included biofilms incubated for 6 h in PBS buffer, DMSO or PLGA 
NPs. Viable cells were determined on blood agar plates. Data represent the mean of three 
independent experiments. Error bars represent standard deviations, and asterisks indicate that 
results are statistically significant compared to the control in the absence of auranofin (one-way 
ANOVA with a post hoc Dunnet test; *, P <0.01; **, P <0.001). 
Figure 5. CLSM of pneumococcal biofilms treated with auranofin-PLGA NPs. Cells of S. 
pneumoniae P046 strain, grown as biofilm, were incubated with PBS (a), or with1 μM of PLGA 
NPs (b), or treated with1 μM of auranofin-PLGA NPs (c) for 6 h at 37 °C. Afterwards, cells in 
the biofilms were stained with the BacLight LIVE/DEAD kit to reveal viable (green 
fluorescence) and non-viable (red fluorescence) bacteria. Horizontal three-dimensional 
reconstructions (x–y plane) are shown. Bars, 25 μm.  
Figure 6. Rescue of zebrafish embryos from pneumococcal infection by auranofin or 
auranofin-PLGA NPs. Survival of embryos infected with S. pneumoniae D39 strain and 
treated (or not) with different concentrations of auranofin or auranofin-PLGA NPs (n═ 24 to 36 
embryos per condition) is shown. Controls with DMSO, auranofin, ampicillin alone and loaded 
into PLGA NPs were also included. Embryos were monitored for survival over a period of 5 
days and results were plotted as Kaplan–Meier survival curves. Survival curves were compared 
with the log-rank (Mantel–Cox) and Gehan–Breslow–Wilcoxon tests (*, P <0.01; **, P 
<0.001). 
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Figure 7. Microscopic images of zebrafish embryos infected with pneumococci and treated 
with auranofin-PLGA NPs. (a) Uninfected embryo group. (b) Embryo group infected with S. 
pneumoniae D39 strain without treatment. (c) Infected embryo group and treated with 0.5 µM 
auranofin-PLGA NPs. Images were taken after 5 days post infection. Abbreviations: pe, 
pericardial edema; tm: tail malformation, and yse, yolk sac edema. Bars, 500 μm. 
 







